beat · 14 stories
DT120, the single-dose LSD pill from Definium, holds an FDA "breakthrough therapy" designation for generalized anxiety disorder. It is Definium's second pivotal Phase 3 win in two months, after a major-depression success.
Cisplatin, gemcitabine, and durvalumab won approval on the strength of the TOPAZ-1 trial, which excluded about a third of real-world patients. A new 1,358-patient international cohort asks if that exclusion was too strict.